Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Phase 3

Completed

• Conditions: Atherosclerosis
• Interventions: Drug: Ateronon

• Registration Number: NCT01287182
• Lead Sponsor: Omicron Pharmaceuticals

Brief Summary

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-01-29
• Study First Submitted QC: 2011-01-31
• Study First Posted: 2011-02-01
• Study Start: 2011-05
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-18
• Last Update Posted: 2013-05-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Men and Women with demonstrated Coronary Disease
• AtheroAbzyme positive during screening process
• Elevated Total Cholesterol
• Willingness to take study nutritional supplement once a day for 3 months

Exclusion Criteria

• Women who are pregnant, nursing or intend pregnancy during the period of treatment
• Known milk, soy or whey allergy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ateronon	Ateronon	-

Primary Outcome Measures

Name	Time	Method
to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease	Baseline and 3 months

Secondary Outcome Measures

Name	Time	Method
to evaluate the potential effectiveness of Ateronon in lowering pulse rate as well systolic and diastolic blood pressure in patients with demonstrated coronary disease	Baseline and 3 months

Trial Locations

Locations (1)

Rafic Hariri University Hospital; 🇱🇧 Beirut, Bir Hasan, Lebanon